TB-500 vs LL-37
Both TB-500 and LL-37 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
TB-500
Evidence BThymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
View full TB-500 profile →LL-37
Evidence BCathelicidin LL-37
The only human cathelicidin antimicrobial peptide. Active against bacteria, viruses, and biofilms. Investigated topically for infected wounds and mucosal infections.
View full LL-37 profile →Side-by-Side
| Attribute | TB-500 | LL-37 |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) | Not FDA-approved — endogenous antimicrobial peptide; clinical trials for infected wounds |
| Typical Dose | 2 mg twice weekly (subcutaneous) | Trial range: topical or intralesional |
| Clinics Indexed | 183 | 19 |
| Categories | recovery, anti-inflammatory | immune, anti-inflammatory |
Key reported benefits — TB-500
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Key reported benefits — LL-37
- ✓Broad antimicrobial activity
- ✓Wound healing
- ✓Anti-biofilm
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.